Lead Product(s): Methyl-GBB
Therapeutic Area: Cardiology/Vascular Diseases
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 05, 2020
Preclinical studies have demonstrated the efficacy of the new molecule in reducing heart infarct size as a result of mitochondrial protection and attenuation of atherosclerosis progression.